Dr. Ni leaded a preclinical study about dendritic cell vaccine on cutaneous T-cell lymphoma (CTCL). By finishing this project, we established the optimal protocol for further clinical study, and we also established a collaborative team of basic immunologists, physician scientists, and clinicians.

Have three ongoing research projects:

One project is implementing to the clinical trial of anti-CCR4 antibody on CTCL. We are assessing the effect of this antibody on regulatory T cells, an immune suppressive cell, if the antibody could reduce or eliminate the Treg, it could be used for many tumors which have increased Tregs.

Another project is to identify the biomarkers for response and resistance to photopheresis for CTCL, and hope that we could find a set of signature genes to help us subgroup patients for better specific therapy indications.

The new project is to find molecular genetic mutations contributing to CTCL and further determine the effect of tumor-associated molecular markers on overall survival, progression free survival and response to targeted therapy.